Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice

Roberto Baccala, Rosana Gonzalez-Quintial, Robert D. Schreiber, Brian R. Lawson, Dwight H. Kono, Argyrios N. Theofilopoulos

Research output: Contribution to journalArticlepeer-review

80 Scopus citations


The demonstration in humans and mice that nucleic acid-sensing TLRs and type I IFNs are essential disease mediators is a milestone in delineating the mechanisms of lupus pathogenesis. In this study, we show that Ifnb gene deletion does not modify disease progression in NZB mice, thereby strongly implicating IFN-α subtypes as the principal pathogenic effectors. We further document that long-term treatment of male BXSB mice with an anti-IFN-α/β receptor Ab of mouse origin reduced serologic, cellular, and histologic disease manifestations and extended survival, suggesting that disease acceleration by the Tlr7 gene duplication in this model is mediated by type I IFN signaling. The efficacy of this treatment in BXSB mice was clearly evident when applied early in the disease process, but only partial reductions in some disease characteristics were observed when treatment was initiated at later stages. A transient therapeutic effect was also noted in the MRL-Faslpr model, although overall mortality was unaffected. The combined findings suggest that IFN-α/β receptor blockade, particularly when started at early disease stages, may be a useful treatment approach for human systemic lupus erythematosus and other autoimmune syndromes.

Original languageEnglish
Pages (from-to)5976-5984
Number of pages9
JournalJournal of Immunology
Issue number12
StatePublished - Dec 15 2012


Dive into the research topics of 'Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice'. Together they form a unique fingerprint.

Cite this